Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Bibliografske podrobnosti
Main Authors:	Mueller, G, Vanderkerken, K, Russell, R, Croucher, P
Format:	Conference item
Izdano:	2004

Podobne knjige/članki

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
od: Mueller, G, et al.
Izdano: (2004)

The Role of Myeloma Cells to Osteoclast Activation
od: Bahare Sadeghi, et al.
Izdano: (2010-01-01)

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
od: Ersek, A, et al.
Izdano: (2015)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
od: Shipman, C, et al.
Izdano: (2000)

An In Vitro Model of Murine Osteoclast-Mediated Bone Resorption
od: Xiaoyue Sun, et al.
Izdano: (2024-11-01)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
od: Edwards, C, et al.
Izdano: (2007)

Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
od: Leng, H
Izdano: (2019)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
od: Croucher, P, et al.
Izdano: (2002)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
od: Mabilleau, G, et al.
Izdano: (2009)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.
od: Mabilleau, G, et al.
Izdano: (2009)

Osteoprotegerin and the development of myeloma bone disease
od: Croucher, P, et al.
Izdano: (2004)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
od: Zhuang, J, et al.
Izdano: (2008)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
od: Dongzheng Gai, et al.
Izdano: (2022-09-01)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
od: Yu-Tzu Tai, et al.
Izdano: (2018-08-01)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
od: Tibullo eDaniele, et al.
Izdano: (2015-10-01)

Bisphosphonates and in vivo models of multiple myeloma - Reply
od: Shipman, C, et al.
Izdano: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
od: Croucher, P, et al.
Izdano: (2000)

Bisphosphonates--mechanisms of action in multiple myeloma.
od: Shipman, C, et al.
Izdano: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
od: Croucher, P, et al.
Izdano: (2003)

The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
od: Jing Fu, et al.
Izdano: (2023-07-01)

BISPHOSPHONATES AFFECT HUMAN OSTEOCLAST DEVELOPMENT IN VITRO
od: Mabilleau, G, et al.
Izdano: (2010)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
od: Vanderkerken, K, et al.
Izdano: (2003)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
od: Zhuang, J, et al.
Izdano: (2007)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
od: Zhuang, J, et al.
Izdano: (2012)

Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids
od: Xu, K, et al.
Izdano: (2009)

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.
od: Minna Qiao, et al.
Izdano: (2015-01-01)

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
od: Maiko Matsushita, et al.
Izdano: (2015-01-01)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
od: Junling Zhuang, et al.
Izdano: (2012-01-01)

In vitro generation of mature human osteoclasts.
od: Hemingway, F, et al.
Izdano: (2011)

In vitro generation of mature human osteoclasts.
od: Hemingway, F, et al.
Izdano: (2011)

Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
od: Kudo, O, et al.
Izdano: (2002)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
od: Liesbeth Bieghs, et al.
Izdano: (2010-01-01)

Effect of amorphous silica nanoparticles on <it>in vitro </it>RANKL-induced osteoclast differentiation in murine macrophages
od: Nagano Kazuya, et al.
Izdano: (2011-01-01)

Osteoclasts and Microgravity
od: John Kelly Smith
Izdano: (2020-09-01)

Estrogen receptor gene expression in osteoclasts loss with osteoclast maturation.
od: Oreffo, R, et al.
Izdano: (1997)

Osteoclast Activation and Inflammatory Bone Diseases: Focusing on Receptors in Osteoclasts
od: Zhao W, et al.
Izdano: (2025-03-01)

NK cells support osteoclast formation in vitro
od: Owen, S, et al.
Izdano: (2004)

Activated T lymphocytes support osteoclast formation in vitro.
od: Horwood, N, et al.
Izdano: (1999)

NK cells support osteoclast formation in vitro
od: Danks, L, et al.
Izdano: (2005)

The effects of seeding density and osteoclastic supplement concentration on osteoclastic differentiation and resorption
od: Stefan J.A. Remmers, et al.
Izdano: (2023-06-01)